- Published at
- by manilatimes.net
positive
positive
News for Akebia Therapeutics, Inc. (AKBA)
- Published at
- by benzinga.com
mixedmixedCrude Oil Gains Over 1%; US Weekly Jobless Claims Increase - Benson Hill (NASDAQ:BHIL), Akebia Therapeutics (NASDAQ:AKBA)
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Thursday. The Dow traded up 0.63% to 42,230.78 whil...- Published at
- by benzinga.com
mixedmixedJOYY, Akebia Therapeutics, Microchip Technology And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Akebia Therapeutics (NASDAQ:AKBA), Enerflex (NYSE:EFXT)
U.S. stock futures were lower this morning, with the Dow futures falling around 200 points on Thursday. Shares of JOYY Inc. YY fell sharply in today's pre-mark...- Published at
- by insidermonkey.com
positivepositive12 Best Stocks to Invest in for a Stock Market Game
We all have heard the phrase ‘value isn’t always visible at first glance’ at least once in our lifetime and this isn’t something to overlook, particularly when you are playing the stock game.- Published at
- by benzinga.com
mixedmixedHallador Energy, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Akebia Therapeutics (NASDAQ:AKBA), Arlo Technologies (NYSE:ARLO)
U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday. Shares of Hallador Energy Company HNRG fell sharply in today's...- Published at
- by seekingalpha.com
positivepositiveAkebia: Still Bullish On Vafseo As Auryxia's Revenues Decline (NASDAQ:AKBA)
Akebia Therapeutics is currently shifting focus from Auryxia to Vafseo due to Auryxia’s declining revenues. See why I reiterate my buy rating for AKBA stock.- Published at
- by gurufocus.com
positivepositiveAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireCAMBRIDGE, Mass., Jan. 2, 2025 CAMBRIDGE, Mass., Jan. 2, 2025 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical co- Published at
- by gurufocus.com
positivepositiveAkebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR NewswireCAMBRIDGE, Mass., Dec. 3, 2024 CAMBRIDGE, Mass., Dec. 3, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical co- Published at
- by gurufocus.com
positivepositiveU.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis
PR NewswireCAMBRIDGE, Mass., Dec. 3, 2024 Outcomes study will assess mortality and hospitalization in patients treated with Vafseo compared to current stan- Published at
- by gurufocus.com
positivepositiveAkebia Therapeutics to Present at the 36th Annual Piper Sandler Healthcare Conference
PR NewswireCAMBRIDGE, Mass., Nov. 25, 2024 CAMBRIDGE, Mass., Nov. 25, 2024 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical- Published at
- by seekingalpha.com
neutralneutralQ3 2024 Earnings: Hold Akebia Therapeutics (NASDAQ:AKBA)
Akebia Therapeutics expands market share with strong Q3 results. See why AKBA stock is gaining momentum, despite potential competition post-2025.- Published at
- by gurufocus.com
positivepositiveAkebia Therapeutics Inc (AKBA) Q3 2024 Earnings Call Highlights: Navigating Revenue Challenges and Preparing for Vafseo Launch
Total Revenue: $37.4 million in Q3 2024, down from $42 million in Q3 2023.AURYXIA Net Product Revenue: $35.6 million in Q3 2024, compared to $40.1 million in Q- Published at
- by gurufocus.com
positivepositiveQ3 2024 Akebia Therapeutics Inc Earnings Call Transcript
Nov 07, 2024 / 01:00PM GMTOperator Good day. And thank you for standing by. Welcome to the Akebia's third quarter, 2024 financial results conference call at thi- Published at
- by seekingalpha.com
neutralneutralAkebia Therapeutics, Inc. (AKBA) Q3 2024 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ETCompany ParticipantsMercedes Carrasco - Senior Director,...- Published at
- by zacks.com
negativenegativeAkebia Therapeutics (AKBA) Reports Q3 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -100% and 18.03%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?- Published at
- by globenewswire.com
neutralneutralChronic Kidney Disease (CKD) Drugs Market is projected to reach USD 23.8 Billion, garnering a 4.2% CAGR from 2024 to 2034: Transparency Market Research, Inc.
The market for medications for chronic kidney disease (CKD) is growing due to an increase in the prevalence of CKD....- Published at
- by globenewswire.com
positivepositiveVerve Therapeutics Announces Appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its Board of Directors
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of...- Published at
- by investing.com
positivepositiveAkebia Therapeutics appoints new CFO By Investing.com
Akebia Therapeutics appoints new CFO- Published at
- by benzinga.com
mixedmixedWhy RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - RH (NYSE:RH)
Shares of RH (NYSE: RH) rose sharply in today’s pre-market trading following the release of quarterly results.- Published at
- by benzinga.com
mixedmixedWhy Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday’s Mid-Day Session - Westport Fuel Systems (NASDAQ:WPRT)
Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected fourth-quarter loss. Westport Fuel Systems posted a quarter loss of 81 cents per share, compared to market expectations for a loss of 51 cents per share.